Blood concentrations of polymorphonuclear leucocyte elastase and interleukin-6 are indicators for the occurrence of multiple organ failures at the early stage of acute pancreatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 12, 1998, Pages 1274-1283

  Ikei, Satoshi ^a,b   Ogawa, Michio ^a   Yamaguchi, Yasuo ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

Acute pancreatitis; Interleukin 6; Polymorphonuclear leucocyte elastase

Indexed keywords

AMYLASE; CYTOKINE; INTERLEUKIN 6; LEUKOCYTE ELASTASE; PANCREATIC ELASTASE;

ACUTE PANCREATITIS; ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032438127     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1998.01793.x     Document Type: Article

References (57)

1. Renner IG, Savage WT, Pantojia JL, Renner VJ. Death due to acute pancreatitis. A retrospective analysis of 405 autopsy cases. Dig. Dis. Sci. 1985; 30: 1005-18.
2. Malech HL, Gallin JI. Current concepts: Immunology. Neutrophils in human disease. N. Engl. J. Med. 1987; 317: 678-94.
3. Weiss SJ. Tissue destruction by neutrophils. N. Engl. J. Med. 1989; 320: 365-76.
4. McGowan SE, Murray JJ. Direct effects of neutrophil oxidants on elastase-induced extracellular matrix proteolysis. Am. Rev. Respir. Dis. 1987; 135: 1286-93.
5. McDonald JA, Kelley DG. Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. J. Biol. Chem. 1980; 255: 8848-58.
6. Mainardi CL, Hasty DL, Sever JM, Kang AH. Specific cleavage of human type III collagen by human polymorphonuclear leukocyte elastase. J. Biol. Chem. 1980; 255: 12006-10.
7. Lankish PG, Rahlf G, Koop H. Pulmonary complications in fatal hemorrhage acute pancreatitis. Dig. Dis. Sci. 1983; 28: 111-16.
8. Tsujimoto M, Yokota S, Vilcek J, Wiessman G. Tumor necrosis factor provokes superoxide generation from neutrophils. Biochem. Biophys. Res. Commun. 1986; 137: 1094-9.
9. Saitoh Y, Yamamoto M. Evaluation of severity of acute pancreatitis. According to a report of the cooperative national survey in Japan. Int. J. Pancreatol. 1991; 9: 51-8.
10. Nathan CF. Secretory products of macrophages. J. Clin. Invest. 1987; 79: 319-26.
11. de Beaux AC, Ross JA, Maingay JP, Fearon KC, Carter DC. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis. Br. J. Surg. 1996; 83: 1071-5.
12. McKay C, Imrie CW, Baxter JN. Mononuclear phagocyte activation and acute pancreatitis. Scand. J. Gastroenterol. 1996; 219 (Suppl.): 32-6.
13. Inagaki T, Hoshino M, Hayakawa T et al. Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis. Pancreas 1997; 14: 1-8.
14. Uomo G, Spada OA, Manes G et al. Neopterin in acute pancreatitis. Scand. J. Gastroenterol. 1996; 31: 1032-6.
15. Takacs T, Farkas Jr G, Czako L, Jarmay K, Mandi Y, Lonovics J. Time-course changes in serum cytokine levels in two experimental acute pancreatitis models in rats. Res. Exp. Med. 1996; 196: 153-61.
16. Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines: New aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40: 522-30.
17. Murata A, Ogawa M, Yasuda T et al. Serum interleukin-6, C-reactive protein and pancreatic secretory trypsin inhibitor (PSTI) as acute phase reactants after major thoraco-abdominal surgery. Immunol. Invest. 1990; 19: 271-8.
18. Leser HG, Gross V, Scheibenbogen C et al. Elevation of interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 191: 782-5.
19. Pezzilli R, Billi P, Miniero R et al. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig. Dis. Sci. 1995; 40: 2341-8.
20. Heath DI, Cruickshank A, Gudgeon M, Jehanli A, Shenkin A, Imrie CW. Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut 1993; 34: 41-5.
21. Scholmerich J. Interleukins in acute pancreatitis. Scand. J. Gastroenterol. 1996; 219 (Suppl.): 37-42.
22. Liras G, Carballo F. An impaired phagocytic function is associated with leukocyte activation in the early stages of severe acute pancreatitis. Gut 1996; 39: 39-42.
23. Willemer S, Feldderson CO, Karges W, Adler G. Lung injury in acute pancreatitis in rats. I. Morphological studies. Int. J. Pancreatol. 1991; 8: 305-21.
24. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am. Rev. Respir. Dis. 1990; 141: 471-501.
25. Weiland JE, Davis WE, Holter JF, Mohammed JR, Dorinsky PM, Gadek JS. Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance. Am. Rev. Respir. Dis. 1986; 133: 218-25.
26. Bergenfeldt M, Berling R, Ohlsson K. Levels of leukocyte proteases in plasma and peritoneal exudate in severe, acute pancreatitis. Can. J. Gastroenterol. 1994; 29: 371-5.
27. Dominguez-Munoz JE, Carballo F, Garcia MJ et al. Monitoring of serum proteinase: Antiproteinase balance and systemic inflammatory response in prognostic evaluation of acute pancreatitis. Results of a prospective multicenter study. Dig. Dis. Sci. 1993; 38: 507-13.
28. Buchler M, Uhl W, Berger HG. Surgical strategies in acute pancreatitis. Hepatogastroenterology 1993; 40: 563-8.
29. Grewal HP, Din AM, Gaber L, Kotb M, Gaber O. Amelioration of physiologic and biochemical changes of acute pancreatitis using an anti-TNF-α polyclonal antibody. Am. J. Surg. 1994; 167: 214-19.
30. Sameshima H, Ikei S, Mori K et al. The role of tumor necrosis factor-α in the aggravation of cerulein-induced pancreatitis in rats. Int. J. Pancreatol. 1993; 14: 107-15.
31. Banks RE, Evans SW, Alexander D, McMahon MJ, Whicher JT. Is fatal acute pancreatitis a consequence of excessive leucocyte stimulation? The role of tumor necrosis factor alpha. Cytokine 1991; 3: 12-16.
32. Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin. Biochem. 1988; 21: 19-25.
33. Messori A, Rampazzo R, Scroccar G et al. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig. Dis. Sci. 1995; 40: 734-8.
34. Buchler M, Malfertheiner P, Uhl W et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104: 1165-70.
35. Cavallii G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. N. Engl. J. Med. 1996; 335: 919-23.
36. Shimazaki E, Tanaka H, Ohta S, Yukioka T, Matsuda H, Shimazaki S. Effects of the antiprotease ulinastatin on mortality and oxidant injury in scalded rats. Arch. Surg. 1995; 130: 994-7.
37. 2 production in human monocytes. Crit. Care Med. 1997; 25: 430-4.
38. Kawamura T, Inada K, Akasaka N, Wakusawa R. Ulinastatin reduces elevation of cytokines and soluble adhesion molecules during cardiac surgery. Can. J. Anaesthesia 1996; 43: 456-60.
39. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am. J. Respir. Crit. Care Med. 1997; 155: 711-18.
40. Usui A, Hiroura M, Kawamura M et al. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Ann. Thorac. Surg. 1996; 62: 1404-11.
41. Shimada M, Matsumura T, Shirabe K, Kamakura T, Taketomi A, Sugimachi K. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection. J. Am. Coll. Surg. 1994; 178: 498-502.
42. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb. Res. 1994; 74: 155-61.
43. Taoka Y, Okajima K, Uchiba M et al. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit. Care Med. 1997; 25: 874-9.
44. Okamura T, Niho Y, Itoga T et al. Treatment of disseminated coagulation and its prodromal stage with gabexate mesilate (FOY): A multi-center trial. Acta Haematologica 1993; 90: 120-4.
45. Ohashi I, Nishijima J, Murata A, Toda H, Kato T. Inhibitory effect of a synthetic protease inhibitor (gabexate mesilate) on the respiratory burst oxidase in human neutrophils. J. Biochem. 1995; 118: 1001-6.
46. Wada Y, Zaima M, Mori K et al. Effect of gabexate mesilate on thrombin and plasmin generation after hepatic resection in cirrhotic patients. Eur. Surg. Res. 1995; 27: 57-62.
47. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Acceleration of phagocytosis in human neutrophils incubated with gabexate mesilate. J. Int. Med. Res. 1994; 22: 292-5.
48. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Inhibitory effect of gabexate mesilate on human neutrophil function. J. Int. Med. Res. 1994; 22: 245-54.
49. Nishiyama T, Aibiki M, Hanaoka K. The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesthesia Analgesia 1996; 82: 108-12.
50. Binns OA, DeLima NF, Buchanan SA et al. Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J. Thorac. Cardiovasc. Surg. 1996; 112: 607-13.
51. Okumura Y, Inoue H, Fujiyama Y, Bamba T. Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats. J. Gastroenterol. 1995; 30: 379-86.
52. Matsuda Y, Kawata S, Nagase T et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Cancer 1994; 73: 53-7.
53. Ito N, Kawata S, Tamura S et al. Induction of interleukin-6 by interferon alpha and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C. Hepatology 1996; 23: 669-75.
54. Hamazaki K, Matsubara N, Yunoki Y, Mori M, Mimura H, Orita K. Effects of ulinastatin on polymorphonuclear leukocyte elastase and interleukin 6 levels after hepatectomy. Clin. Therapeutics 1994; 16: 680-5.
55. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am. J. Surg. 1996; 171: 394-8.
56. Tamakuma M, Shiba T, Hirasawa H, Ogawa M, Nakajima M. A dose-finding study of a neutrophilekastase inhibitor; ONO-5046·Na in lung injury of SIRS patients. Rinsou Iyaku 1998; 14: 263-88 (in Japanese).
57. Tamakuma M, Shiba T, Hirasawa H, Ogawa M, Nakajima M. A phase III clinical study of a neutrophil elastase inhibitor: ONO-5046·Na in SIRS patients. Rinsou Iyaku 1998; 14: 289-318 (in Japanese).